UCB S.A.: PharmaVitae Profile

Publication Date	November 2007
Publisher	Datamonitor
Product Type	Report
Pages	148
ISBN Number	not applicable
Product Code	DAT03304

Price

£3,010.00
approximately: $4,398 | €3,299

PDF

PRINT £3,045 ($4,449 | €3,337)

Order above formats by FAX

Summary

Introduction

This analysis examines the historical and forecast performance for UCB in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

Benchmark UCB's performance against key rivals in the ethical pharmaceutical sector
Assess UCB's M&A-driven diversification into the biopharmaceuticals sector, under-scored by the impending launch of Cimzia
Analyze UCB's impressive forecast sales growth performance over 2006-12, with revenues expected to grow at a CAGR of 11.4%

Content

Chapter 1 Executive Summary
- Key Findings
- Historical And Forecast Ethical Sales Performance
- Therapeutic Strategy
- Launch And Expiry Outlook
- Externalization, Geographic And Molecule Type Strategies
- Externalization Strategy
- Geographic Strategy
- Molecule Type Strategy
- Swot Analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
Chapter 2 Corporate History
- Key Findings
- Background
- Key Corporate Developments
- M&A History
- Celltech
- Schwarz Pharma
- M&A Strategy
- Current Corporate Structure
- Current Management Team
Chapter 3 Historical Performance
- Key Findings
- Introduction
- Revenue And Growth Rate Analysis, 2001-06
- Revenue And Growth Rate Vs. Peer Set
- Product Analysis, 2001-06
- Growth Drivers
- Keppra
- Xyzal
- Growth Resistors
- Zyrtec
- Operating Revenue And Cost Analysis, 2001-06
- Operating Revenue/Cost Analysis
Chapter 4 Forecast Performance
- Key Findings
- Introduction
- Revenue And Growth Rate, 2006-12
- Product Analysis, 2006-12
- Growth Drivers
- Cimzia
- Vimpat
- Neupro
- Rikelta
- Keppra
- Xyzal
- Growth Resistors
- Zyrtec
- Omeprazole
- Therapy Area Analysis, 2006-12
- Growth Drivers
- Cns
- I&I
- Urology & Sexual Health
- Growth Resistors
- Gastroenterology
- Therapy Area Focus
- Launches And Expiries Analysis, 2006-12
- Launch Portfolio
- Core Portfolio
- Expiry Portfolio
- Launch/Core/Expiry Configuration
- Externalization Analysis, 2006-12
- Geographic Analysis, 2006-12
- Molecule Type Analysis, 2006-12
Chapter 5 Key Products And Competitors
- Key Findings
- Overview
- Central Nervous System
- Keppra
- Overview
- Sales Forecast
- Newsflow
- Competitive Landscape
- Current Market Assessment
- Future Market Assessment
- Vimpat
- Overview
- Sales Forecast
- Newsflow
- Competitive Landscape
- Future Market Assessment
- Neupro
- Overview
- Sales Forecast
- Newsflow
- Competitive Landscape
- Future Market Assessment
- Immunology & Inflammation
- Cimzia
- Overview
- Sales Forecast
- Newsflow
- Competitive Landscape
- Future Market Assessment
- Respiratory
- Xyzal
- Overview
- Sales Forecast
- Newsflow
- Competitive Landscape
- Current Market Assessment
- Future Market Assessment
- R&D Pipeline
Chapter 6 Appendix
- Ims Vs. Company-Reported Data Reconciliation
- References
- Abbreviations
- Exchange Rates
List Of Tables
- Table 1: Roche Group Corporate Executive Committee
- Table 2: Historical Sales By Company ($M)
- Table 3: Mid Pharma Peer Set Overview
- Table 4: Operating Revenue/Cost Analysis ($M), 2001-06
- Table 5: Operating Cost Ratio Analysis (% Of Total Revenues), 2001-06
- Table 6: Product Portfolio Overview, Sales ($M), 2006-12
- Table 7: Therapy Area Overview, Sales ($M), 2006-12
- Table 8: Launch Portfolio Overview, Sales ($M), 2006-12
- Table 9: Core Portfolio Overview, Sales ($M), 2006-12
- Table 10: Expiry Portfolio Overview, Sales ($M), 2006-12
- Table 11: Externally Developed Portfolio, 2006-12 ($M)
- Table 12: Molecule Type Overview, Sales ($M), 2006-12
- Table 13: Key Products Overview
- Table 14: Keppra: Overview
- Table 15: Keppra: Sales Forecast ($M), 2006-12
- Table 16: Keppra: Newsflow
- Table 17: Vimpat: Overview
- Table 18: Vimpat: Sales Forecast ($M), 2006-12
- Table 19: Vimpat: Newsflow
- Table 20: Neupro: Overview
- Table 21: Neupro: Sales Forecast ($M), 2006-12
- Table 22: Neupro: Newsflow
- Table 23: Cimzia: Overview
- Table 24: Cimzia: Sales Forecast ($M), 2006-12
- Table 25: Cimzia: Newsflow
- Table 26: Xyzal: Overview
- Table 27: Xyzal: Sales Forecast ($M), 2006-12
- Table 28: Xyzal: Newsflow
- Table 29: Ucb's R&D Pipeline (Phase I-Registration)
- Table 30: Exchange Rates, 2006
List Of Figures
- Figure 1: Historical And Forecast Ethical Sales Performance (% Cagr), Ucb And Big Pharma Peer Set
- Figure 2: Therapeutic Focus Vs. Mid Pharma Peer Set (%), 2006
- Figure 3: Launch, Core And Expiry, Absolute Sales Growth, 2006-12 (Sales As % Of 2006 Sales), Ucb
- Figure 4: Launch, Core And Expiry, Absolute Sales Growth, 2006-12 (Sales As % Of 2006 Sales), Mid Pharma
- Figure 5: Molecule Type, Externalization And Geographic Market Dependency (%) Vs. Peer Set, 2006
- Figure 6: Molecule Type, Externalization And Geographic Market Dependency (%) Vs. Peer Set, 2012
- Figure 7: Swot Analysis Of Ucb
- Figure 8: M&A/Divestment History
- Figure 9: Revenue & Growth Rate (Ethical Sales) ($M), 2001-06
- Figure 10: Revenues By Company, Ethical Sales ($M), 2001-06
- Figure 11: Ethical Revenue ($M) And Growth Rate (%) Vs. Peer Set, 2001-06
- Figure 12: Growth Drivers/Resistor Products Of Historical Revenue Performance ($M), 2001-06
- Figure 13: Operating Revenue/Cost Analysis ($M), 2001-06
- Figure 14: Operating Cost Ratio Analysis (% Of Total Revenues), 2001-06
- Figure 15: Ethical Revenue ($M) And Growth Rate (%), 2006-12
- Figure 16: Top Five Products By Sales ($M), 2006
- Figure 17: Top Five Products By Sales ($M), 2012
- Figure 18: Growth Drivers And Resistors By Product, 2006-12
- Figure 19: Key Strategic Products, Sales ($M), 2006-12
- Figure 20: Ethical Sales By Therapy Area ($M), 2006-12
- Figure 21: Growth Drivers And Resistors By Therapy Area (%), 2006-12
- Figure 22: Ethical Sales By Therapy Area (%), 2006-12
- Figure 23: Therapy Area Focus Compared With Peer Set (% Total Ethical Sales), 2006
- Figure 24: Therapy Area Focus Compared With Peer Set (% Total Ethical Sales), 2012
- Figure 25: Launch Schedule, Sales ($M), 2006-12
- Figure 26: Core Products Sales Growth ($M), 2006-12
- Figure 27: Expiry Schedule, Sales ($M), 2006-12
- Figure 28: Launch, Core And Expiry, Sales ($M), 2006-12
- Figure 29: Launch, Core And Expiry, Absolute Sales Growth, 2006-12 (Sales As % Of 2006 Sales), Ucb
- Figure 30: Launch, Core And Expiry, Absolute Sales Growth, 2006-12 (Sales As % Of 2006 Sales), Peer Set
- Figure 31: Externalization Dependency, Sales ($M), 2006-12
- Figure 32: Growth Drivers And Resistors, Externally Vs. Internally Discovered Products, Sales ($M), 2006-12
- Figure 33: Externalization Dependency Vs. Peer Set, % Total Sales, 2006
- Figure 34: Externalization Dependency Vs. Peer Set, % Total Sales, 2012
- Figure 35: Geographical Sales Breakdown ($M), 2006-12
- Figure 36: Growth Drivers And Resistors By Geography, Sales ($M), 2006-12
- Figure 37: Us Dependency Vs. Peer Set, % Total Sales, 2006
- Figure 38: Us Dependency Vs. Peer Set, % Total Sales, 2012
- Figure 39: Molecule Type Sales Breakdown ($M), 2006-12
- Figure 40: Growth Drivers And Resistors By Molecule Type, Sales ($M), 2006-12
- Figure 41: Biologics Dependency Vs. Peer Set, % Total Sales, 2006
- Figure 42: Biologics Dependency Vs. Peer Set, % Total Sales, 2012
- Figure 43: Ims Vs. Company-Reported Ethical Sales Discrepancy ($M), 2006
- Figure 44: Ims Vs. Company-Reported Ethical Sales Forecast Growth Rates (%), 2006-12